Mobility & Recovery

Frequently Asked Questions

What peptides are Canadian owners researching for pet mobility and recovery?
Ten products make up Pet Peptides Canada's mobility and recovery category, including BPC-157, TB-500, SS-31, and a combined BPC-157 TB-500 blend, all researched for joint, tendon, and soft tissue support. Canadian owners exploring mobility questions for an aging or active dog can compare every option side by side on one page.

How does the combined BPC-157 TB-500 blend differ from buying each peptide separately in Canada?
A dual action recovery protocol, not two separate purchases, is how Pet Peptides Canada positions its BPC-157 5mg plus TB-500 5mg blend, aimed at healing, inflammation, and joint or tendon recovery together. Canadian owners researching combined mobility support can compare its price directly against buying the two peptides individually.

Can TB-500 be researched for speeding up recovery in an active dog in Canada?
Thymosin Beta-4 is the fuller name behind TB-500, available at 5mg and 10mg through Pet Peptides Canada and studied for recovery speed, inflammation reduction, and performance related research. Canadian owners with an active or working dog often research it alongside BPC-157 within the same mobility and recovery category.

I want a single formula that addresses several recovery goals for my pet in Canada.
Multiple recovery pathways in one formula is the idea behind KLOW, an 80mg blend sold through Pet Peptides Canada instead of requiring separate purchases for each compound researchers care about. Canadian owners researching systemic recovery support for an active or aging pet can weigh KLOW's price against building a stack from single peptides.

Should a first time Canadian researcher start with 5mg or 10mg BPC-157?
5mg or 10mg is the first real decision most people face with BPC-157, and Pet Peptides Canada lists both strengths in its mobility category for Canadian owners to compare. Reading the site's blog content alongside both listings tends to make that starting strength decision, especially for a first research plan, much clearer.